NattoPharma, now a part of Gnosis by Lesaffre, has secured patents in Canada and South Korea for its synthesis of MenaQ7 PharmaPure Vitamin K2 as MK-7, bolstering the company’s patent portfolio.
In Canada, patent #22,888,010 “Process for preparation of MK-7 type of vitamin K2” was granted on May 25, 2021, while in South Korea, patent #10-2229841 “Process for preparation of MK-7 type vitamin K2” was issued on March 15, 2021.
“This unique patented process results in the world’s only truly all-trans synthetic vitamin K2 as MK-7,” said William Sommer, NattoPharma’s VP of Global Development & Regulatory. “Our material is recognised as being of the highest quality, to which it is currently being utilised in multiple studies sponsored by the traditional medical community. This technology also ensures supplement manufacturers deliver the MK-7 with the health benefits customers desire.”
The company says it has made significant intellectual and monetary investments in technologies, and is committed to monitoring market developments to protect the company’s intellectual property rights throughout their lifespan.
“The approval of these patents represents another milestone for NattoPharma and its partners,” said Sophie Legrain-Raspaud, Global Research and Applications Director with Gnosis by Lesaffre. “This further strengthens our combined global IPR‐platform and improves our competitive position within the food supplement market. It is a wonderful development for NattoPharma and conveys the overwhelming promise of our recent merger.”
